4
ALL4
UTILITY therapeuticsYear
4
ALL2
20242
2021DEALS // DEV.
4
ALL1
Deals3
DevelopmentsCountry
4
ALL4
UNITED KINGDOM4
ALL1
AMR Action Fund3
Not ApplicableTherapeutic Area
4
ALL4
Infections and Infectious DiseasesStudy Phase
4
ALL3
Approved1
Phase IIIDeal Type
1
ALL1
FinancingProduct Type
4
ALL4
Small moleculeDosage Form
4
ALL4
TabletLead Product
4
ALL4
PivmecillinamTarget
2
ALL2
PBP1ALead Product(s) : Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves New Treatment for Uncomplicated Urinary Tract Infections
Details : Pivya (pivmecillinam) oral tablets are FDA-approved for uncomplicated UTIs in adult females caused by susceptible E. coli, Proteus mirabilis, and Staphylococcus saprophyticus.
Product Name : Pivya
Product Type : Small molecule
Upfront Cash : Not Applicable
April 24, 2024
Lead Product(s) : Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : AMR Action Fund
Deal Size : Undisclosed
Deal Type : Financing
Utility Therapeutics Ltd. Announces Financing Led By AMR Action Fund and FDA Acceptance
Details : Proceeds develop and commercialize European-approved antibiotics Pivya (pivmecillinam), an oral prodrug of mecillinam, and mecillinam, an intravenous (IV) formulation for UTIs.
Product Name : Pivya
Product Type : Small molecule
Upfront Cash : Undisclosed
January 17, 2024
Lead Product(s) : Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : AMR Action Fund
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
UTILITY Therapeutics to Present Data at IDWeek 2021
Details : Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended spectrum beta-lactamases.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
September 29, 2021
Lead Product(s) : Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
UTILITY Therapeutics Preparing NDA Submission
Details : Pivmecillinam is an oral prodrug of mecillinam that is being developed for uncomplicated UTI (uUTI), and it has a unique mechanism of action for infections caused by Gram-negative bacteria, including extended-spectrum beta-lactamases.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
June 15, 2021
Lead Product(s) : Pivmecillinam
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable